Amgen Repatha Phase 3 Trial Meets Dual Primary Endpoints for Primary Cardiovascular Prevention

Amgen Inc. (NASDAQ:AMGN) is one of the best growth stocks to buy now. On October 2, Amgen announced that its landmark Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints, confirming that ...
Zacks Investment Research on MSN

Amgen Unveils New DTC Program, Cuts Cholesterol Drug Price by 60%

This discount announcement comes just a few days after Amgen reported positive data from a late-stage study, which showed that treatment with Repatha significantly reduced the risk of major adverse ...
The American Journal of Managed Care

Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms

In alignment with the Trump administration’s efforts to lower drug prices, Amgen today launched AmgenNow, a direct-to-patient program offering evolocumab (Repatha) at a monthly price of $239, nearly ...

A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism

Amgen (AMGN) is making waves after its VESALIUS-CV Phase 3 trial demonstrated that Repatha significantly lowers major ...
Morningstar

Amgen's Repatha Phase 3 Trial Meets Dual Primary Endpoints

Amgen's late-stage study of human monoclonal antibody Repatha hit its dual primary targets, demonstrating it significantly reduced the risk of major adverse cardiovascular events in individuals ...